What's new
Information from the previous month appears monthly in the newsletter “What'sNew” (link to registration page).
For the RSS feed with daily notifications of updates, use the link: RSS feed for “What'sNew”.
22/04/2025
Microsoft Word - L_I285_Guidance Notes _National Stockpiling Guidance notes for the notification of national stockpiling L_INS_VIE_EVEQ_I285_02 Valid from: 22.04.2025 1/22 Guidance notes for the notif
Referenced at:
Acenocoumarol New
PSUR-outcome
|
22/04/2025
Further information and amendments to the product information in all EU languages are available on the EMA website.
Levonorgestrel IUS New
Additional template
|
22/04/2025
Further information can be found in the CMDh minutes from february 2025.
21/04/2025
Clinical trials of medicinal products Overview BASG fee schedule for clinical studies Withdrawal for technical reasons Information and training material BASG fee schedule for clinical studies As of 01
Busulfan New
PSUR-outcome
|
15/04/2025
Further information and amendments to the product information in all EU languages are available on the EMA website.
Capecitabine New
PSUR-outcome
|
15/04/2025
Further information can be found in the Commission Decision and its annexes, which are available in all EU languages on the European Commission's (EC) website.
15/04/2025
Scientific advice by BASG New Scientific advice in the development of medicinal products The objective of such national scientific advices is to discuss with BASG scientific matters regarding the deve
15/04/2025
EU IN communication on SNSA transition to 2025 7th February 2025 Simultaneous National Scientific Advice (SNSA) - Continuation and further development during 2025 Since February 2020, the EU Innovatio
Referenced at:
Safety warnings
|
Medical devices
|
14/04/2025
The Federal Office for Safety in Health Care (BASG) has been informed that the manufacturer SEBBIN, which went bankrupt in March 2025, has no legal successor who continues to fulfil the manufacturer obligations arising from the Regulation (EU) 2017/745 on medical devices („MDR“), as amended.
Tiagabine New
PSUR-outcome
|
07/04/2025
Further information and amendments to the product information in all EU languages are available on the EMA website.